Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria vaccine. BioStock talked to CEO Bent U. Frandsen about this at the partnering conference BIO-Europe.

See the interview below.

Prenumerera på BioStocks nyhetsbrev